Is Pharma’s IRA Pricing Battle Running Out of Steam?

Is pharma’s IRA pricing battle running out of steam?

Despite recent court losses, the legal tides could still turn in the industry’s favor.

Pharma’s Uphill Battle Against IRA Drug Pricing: Legal Setbacks and Future Prospects

The pharmaceutical industry’s efforts to overturn the drug pricing program established under the Inflation Reduction Act (IRA) appear to be stalling as major companies like Novartis, Bristol Myers Squibb (BMS), and Johnson & Johnson face a series of legal defeats. Despite these setbacks, the industry remains undeterred, with the recent dissent by Judge Thomas Hardiman in a Third Circuit Court of Appeals case offering a glimmer of hope. The disse…